CoChat

Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands

Open access
Hunt, Barnaby, Malkin, Samuel J P, Moes, Robert G J, Huisman, Eline L, Vandebrouck, Tom, Wolffenbuttel, Bruce H R · 2019 · BMJ Open Diabetes Research & Care
Cited by 42

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Objective: Choosing therapies for type 2 diabetes that are both effective and cost-effective is vital as healthcare systems worldwide aim to maximize health of the population. The present analysis assessed the cost-effectiveness of once-weekly semaglutide (a novel glucagon-like peptide-1 (GLP-1) receptor agonist) versus insulin glargine U100 (the most commonly used basal insulin) and versus dulaglutide (an alternative once-weekly GLP-1 receptor agonist), from a societal perspective in the Netherlands. Research design and methods: The IQVIA CORE Diabetes Model was used to project outcomes for once-weekly semaglutide 0.5 mg and 1 mg versus insulin glargine U100, once-weekly semaglutide 0.5 mg versus dulaglutide 0.75 mg, and once-weekly semaglutide 1 mg versus dulaglutide 1.5 mg. Clinical data were taken from the SUSTAIN 4 and SUSTAIN 7 clinical trials. The analysis captured direct and indirect costs, mortality, and the impact of diabetes-related complications on quality of life. Results: Projections of outcomes suggested that once-weekly semaglutide 0.5 mg was associated with improved quality-adjusted life expectancy by 0.19 quality-adjusted life years (QALYs) versus insulin glargine U100 and 0.07 QALYs versus dulaglutide 0.75 mg. Once-weekly semaglutide 1 mg was associated with mean increases in quality-adjusted life expectancy of 0.27 QALYs versus insulin glargine U100 and 0.13 QALYs versus dulaglutide 1.5 mg. Improvements came at an increased cost versus insulin glargine U100, with incremental cost-effectiveness ratios from a societal perspective of €4988 and €495 per QALY gained for once-weekly semaglutide 0.5 mg and 1 mg, respectively, falling below Netherlands-specific willingness-to-pay thresholds. Improvements versus dulaglutide came at a reduced cost from a societal perspective for both doses of once-weekly semaglutide. Conclusions: Once-weekly semaglutide is cost-effective versus insulin glargine U100, and dominant versus dulaglutide 0.75 and 1.5 mg for the treatment of type 2 diabetes, and represents a good use of healthcare resources in the Netherlands.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmjdrc-2019-000705

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Research works printed but not linked: 24

  1. 10.1007/s00125-002-0815-8 · doi:10.1007/s00125-002-0815-8
  2. 10.1016/S0140-6736(98)07019-6 · DOI · Paper page
  3. 10.1136/bmj.317.7160.703 · DOI · Paper page
  4. 10.2337/dc07-2452 · DOI · Paper page
  5. Peters, 2017, The current total economic burden of diabetes mellitus in the Netherlands, Neth J Med, 75, 281
  6. 10.2337/diacare.27.9.2262 · DOI · Paper page
  7. Palmer, 2004, The core diabetes model: projecting long-term clinical outcomes, costs and Costeffectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making, Curr Med Res Opin, 20, S5, 10.1185/030079904X1980 · DOI · Paper page
  8. Palmer, 2004, Validation of the core diabetes model against epidemiological and clinical studies, Curr Med Res Opin, 20 Suppl 1, S27, 10.1185/030079904X2006 · DOI · Paper page
  9. McEwan, 2014, Validation of the IMS core diabetes model, Value in Health, 17, 714, 10.1016/j.jval.2014.07.007 · DOI · Paper page
  10. Aroda, 2017, Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (sustain 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3A trial, Lancet Diabetes Endocrinol, 5, 355, 10.1016/S2213-8587(17)30085-2 · DOI · Paper page
  11. Pratley, 2018, Semaglutide versus dulaglutide once Weekly in patients with type 2 diabetes (sustain 7): a randomised, open-label, phase 3B trial, Lancet Diabetes Endocrinol, 6, 275, 10.1016/S2213-8587(18)30024-X · DOI · Paper page
  12. Hunt, 2017, Evaluation of the long-term cost-effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the UK setting, Diabetes Obes Metab, 19, 842, 10.1111/dom.12890 · DOI
  13. Mezquita-Raya, 2017, Liraglutide versus Lixisenatide: long-term cost-effectiveness of GLP-1 receptor agonist therapy for the treatment of type 2 diabetes in Spain, Diabetes Ther, 8, 401, 10.1007/s13300-017-0239-6 · DOI
  14. Sørensen, 2013, The cost of diabetes-related complications: registry-based analysis of days absent from work, Economics Research International, 2013, 1, 10.1155/2013/618039 · DOI
  15. Beaudet, 2014, Review of utility values for economic modeling in type 2 diabetes, Value Health, 17, 462, 10.1016/j.jval.2014.03.003 · DOI · Paper page
  16. Evans, 2013, Health-Related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries, Health Qual Life Outcomes, 11, 10.1186/1477-7525-11-90 · DOI · Paper page
  17. Vemer, 2011, Largely ignored: the impact of the threshold value for a QALY on the importance of a transferability factor, Eur J Health Econ, 12, 397, 10.1007/s10198-010-0253-3 · DOI
  18. Bobinac, 2010, Willingness to pay for a quality-adjusted life-year: the individual perspective, Value in Health, 13, 1046, 10.1111/j.1524-4733.2010.00781.x · DOI
  19. Johansen P , Håkan-Bloch J , Liu AR , et al . Cost effectiveness of once-weekly Semaglutide versus once-weekly Dulaglutide in the treatment of type 2 diabetes in Canada. Pharmacoecon Open 2019;127.doi:10.1007/s41669-019-0131-6 · DOI
  20. Malkin, 2019, Once-Weekly Semaglutide versus once-daily liraglutide for the treatment of type 2 diabetes: a long-term cost-effectiveness analysis in Estonia, Diabetes Ther, 10, 159, 10.1007/s13300-018-0542-x · DOI
  21. Gæde P JP , Tikkanen CK , Pollock RF , et al . Management of patients with type 2 diabetes with once-weekly Semaglutide versus Dulaglutide, exenatide ER, liraglutide and Lixisenatide: a cost-effectiveness analysis in the Danish setting. Diabetes Ther 2019. · DOI
  22. Gerstein, 2019, Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial, The Lancet, 394, 121, 10.1016/S0140-6736(19)31149-3 · DOI · Paper page
  23. 10.1056/NEJMoa1612917 · DOI · Paper page
  24. Evan, 2018, The importance of incorporating cardio-protective effects of once-weekly semaglutide, Diabetologia, 61, 427

Cited by

See all 42

Metadata

Authors
Hunt, B., Malkin, S. J. P., Moes, R. G. J., Huisman, E. L., Vandebrouck, T., & Wolffenbuttel, B. H. R.
Venue
BMJ Open Diabetes Research & Care
Publisher
BMJ
Published
2019-10
Volume
7
Issue
1
Pages
e000705
ISSN
2052-4897 (ISSN-L)
OpenAlex
W2979241049
Cited by
42
References
11
FWCI
2.93
Type
journal article
Language
en
Open access
gold
Funders
Novo Nordisk Region Europe Pharmaceuticals A/S

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands. https://app.cochat.ai/papers/10.1136/bmjdrc-2019-000705
The paper
Hunt, B., Malkin, S. J. P., Moes, R. G. J., Huisman, E. L., Vandebrouck, T., & Wolffenbuttel, B. H. R. (2019). Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands. BMJ Open Diabetes Research & Care. https://doi.org/10.1136/bmjdrc-2019-000705

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.